Several clinical trials, such as VERVE-101, are currently evaluating in vivo CRISPR-based therapies targeting PCSK9 in patients with heterozygous FH, aiming to achieve long-term LDL-C reduction with a single-dose treatment. Here, PCSK9 is linked to familial hyperaldosteronism.